Skip to main content

Table 6 Recommendations for stakeholders

From: Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries

Based on this survey, we recommend that CSOs:
• conduct HCV epidemiology studies in key populations;
• integrate HCV services in PWID and PLHIV programs;
• monitor PWID access to HCV treatment; document, disseminate and, if appropriate, pursue legal and media options for any cases of service denial;
• advocate for inclusion of PWID in national HCV guidelines and programs;
• advocate for HCV medication price reductions through stakeholders and the media;
• monitor the drug registration landscape and maintain pressure on pharmaceutical companies and governments for prompt registration of new drugs;
• partner with international organizations to oppose barriers and leverage TRIPS flexibilities;
• work with governments on regulatory measures to ensure lower prices for generics;
• advocate for government disclosure of prices, purchase volumes and relevant treatment program details to allow independent expert evaluation;
• participate on national HCV program advisory committees;
• participate in advocacy related to keeping WHO guidelines updated;
• include HCV testing and treatment in project proposals, with focus on key populations but also considering the general population;
• document and disseminate CSO-led HCV program best practices.